



Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
U.S.A.

Henri A. Termeer
Chairman and Chief Executive Officer

April 21, 2010

To our patient communities,

Genzyme's mission is and has always been to improve the lives of patients with complex diseases. With this mission comes tremendous responsibility. While we continue to make progress in our path to re-establishing consistent, reliable supplies of Cerezyme[®] (imiglucerase for injection) and Fabrazyme[®] (agalsidase beta), we have recently experienced a moment in our history when this progress has been temporarily interrupted.

We have worked diligently to address the issues related to the Allston Landing manufacturing facility, and we will continue to work with stakeholders from the community in our efforts to manage the resulting extension of the current Cerezyme and Fabrazyme shortages as efficiently and fairly as possible.

We deeply regret and understand the disappointment for those in the Gaucher and Fabry disease communities affected by this change in our ability to supply. We take our responsibility to provide the therapies you depend upon very seriously. We are completely focused on confronting and resolving the manufacturing challenges that we currently face and restoring a consistent supply of these products.

Each and every one of us here at Genzyme is committed to re-earning your trust. The only way this will happen is if we return to a reliable supply of products, produced in world-class manufacturing facilities. We are working hard to make this happen and will not let anything distract us from our responsibility and commitment to you.

Sincerely,

Henri A. Termeer